Galapagos extends drug discovery collaboration with Lilly in nuclear hormone receptor research
The agreement extension builds on the successful collaboration begun in March 2005. BioFocus DPI has been working with Lilly on discovering new compounds that target nuclear hormone receptors, a class of proteins that, when bound to specific sequences of DNA, serve as on-off switches for controlling the development and differentiation of skin, bone, and behavioral centers in the brain, as well as the continual regulation of reproductive tissues. With this agreement, Lilly secures continued access to BioFocus DPI's screening and biology expertise to discover compounds which "hit" these nuclear hormone receptors.
The extension agreement is unrelated to the major collaboration with Lilly in osteoporosis that Galapagos announced on 19 December 2007, in which Galapagos' drug discovery division will be responsible for the development of novel osteoporosis drug candidates potentially through to phase IIa clinical Proof of Concept.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.